At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Pembrolizumab +2 moredrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pembrolizumab in Combination With Platinum-based Chemotherapy in Nonsmall Cell Lung Cancer Patients With Targetable Genetic Alterations Previously Treated With Appropriate Targeted Agents With Progressive Disease
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, Carboplatin, and 1 other intervention for Non-small Cell Lung Cancer. Completed, enrolled 33 participants across 7 sites.
Detailed Summary
Investigators hypothesize that addition of pembrolizumab will enhance the efficacy of carboplatin and pemetrexed in patients with EGFR-mutation-positive NSCLC, or patients with other genetic alterations, and who have disease progression following appropriate targeted therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartOct 2017
Primary CompletionFeb 2025
TodayJul 2026
First PostedAug 8, 2017
Enrollment StartOct 3, 2017
Primary CompletionFeb 20, 2025
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 8.9 years ago
Interventions
Pembrolizumabdrug
200mg IV every 3 weeks
Carboplatindrug
AUC 5 IV every 3 weeks
Pemetrexeddrug
500 mg/m\^2 IV every 3 weeks